Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks,do you think all the gaps below here will get filled ?
$3.53 from February 24
$4.70 from January 02
Hey Ryman, what are the gaps above this level, Thanks
Agreed, seems like the bottom is in. Best of luck!!
The end is nigh! The end is nigh! Oh no, Oh no! my average PPS is $4!
Yes, could be good entry point or for some to average down.
I was waiting for capitulation in the market, but couldn't resist dipping a toe in here. Didn't think we'd see sub $2 again. Throwing the baby out with the bathwater. People will still need the products that Antares sells or partners.
Antares Pharma Is Maintained at Strong Buy by Raymond James
7:31 AM ET 3/4/20 | Dow Jones
Ratings actions from Benzinga: https://www.benzinga.com/stock/ATRS/ratings
> Dow Jones Newswires
March 04, 2020 07:31 ET (12:31 GMT)
Oh the pain! My hole has been cored out on this one. I got in at around 4.+
Oh the pain! My hole has been cored out on this one. I got in at around 4.+
Ready to ride once again! Got 1000 @ $3.45 and another 5370 at $3.53 - that 3.53 took 12 fills to fill the order lol in the last 30 minutes of trading today.
Hi again CN. No updates from Larry Smith, but I’m guessing there will be one in a few weeks, maybe after Antares reports their fourth quarter and full year results and the 10-K is filed. BTW- they haven’t cut forecasts, they only provided conservative guidance of about 20% growth. Based on the prescription data, I think Antares will at least break even or earn a small profit this quarter, (a penny) and I anticipate at least modest growth and profitability going forward. The stock price doesn’t always reflect the value of these small companies, but turning the profitability corner is a big positive, and after the recent sell-off, I think ATRS is undervalued. When the uncertainty about the status of Makena and timing of the generic Forteo launch are known, (Teva now says end of 2020 or early 2021) it could give the shares a lift. A little clarity on the pipeline would also help and that should also be known soon. As far as the slowing growth of Xyosted, I think it’s just temporary, and growth will pick back up, but there’s only so much you can do with their limited sales staff and budget.
I’ve always been a long-term investor, but after watching paper profits washed away with these small companies, (ATRS, BLFS & CYRX, etc.) in the last few years, I’ve become more of a long-term trader due to the volatility and games that are played with these stocks. By buying when the price is low (like after the CRL & now) you can then sell individual lots when the price appreciates. Like the old saying goes - If you can’t beat ‘em, join ‘em.
Thanks for the reply, I'm longer than ever and questioning my wisdom in still being so bullish. I'm just hopeful they can string a few profitable quarters together and beat estimates as they have been. Still think this is low risk with so many different revenue sources.
I don't have a subscription to SOS. I didn't see any indication that he had a recent update. I made another small purchase of a few more shares of ATRS. Not sure what the future holds for ATRS, but imo it's more than just Xyosted. I have tempered my expectations for the stock price in 2020 but I'm still bullish and long the stock.
luvgrowth indicated that this would go back to $3.50 to fill the gap and low and behold, he was correct.
Does anyone have a subscription so SoS? Has he posted anything on ATRS since they essentially cut forecast/scripts leveled off?
Added. Not sure what the recent stock weakness is about. In the absence of news I will continue to hold and add on any subsequent dips.
On second thought, after being involved in an OTC, penny stock, where a CEO repeatedly lied for years about earning being high and hid behind the "safe harbor act" I guess I'm ok with a CEO low-balling the sales and profits and hope that he's going to under promise and over deliver.
In summary, it's better to under-promise and over-deliver and if sale and profits are above projections, it could or should cause the share price to rise, if there isn't massive dilution, or crazy secondary, toxic-style financing and provided that the company is not sued or in major debt.
The worst case scenario is that sale and profits are hyped up too much and they mis the mark, then the stock price takes shat.
Ya, what a blunder!!! We are screwed! Maybe even he doesn't believe in the success of his own pharma?
I guess Bob Apple got a little heat for their silence while the stock price got pushed below $4, but really? Revenue guidance range of $135 to $155 Million, after announcing that full-year 2019 revenue is expected to be at the upper end or exceeding revenue guidance of $115 to $120 million? They only estimate ~15% - 25% growth this year? I’m all for under-promising and over-delivering, but c’mon man, that is more like the worst-case scenario of Makena immediately taken off the market, zero revenue from Gx Forteo, and low growth of Xyo and Epi. I haven’t updated my model since Q3, but I’ve got $122M for 2019, and $170 for this year, and I thought that was being conservative.
There definitely would be a market for a rescue pen to replace a syringe administered treatment for hypoglycemia. But there's no evidence that Pfizer is working with Zealand.
I am disappointed that more detailed information on the deal with Pfizer hasn't been released. I know it's up to Pfizer to decide when to do that. But I'm starting to wonder if there's a snag somewhere. It doesn't appear that anything is imminent.
From the yahoo board
SilverFox10 hours ago
FYI: Potential drug Pfizer utilizing Antares Rescue Pen
I came across a ‘potential’ combination drug device rescue pen that Pfizer may be working on in which they have agreed to partner with ATRS per press release dated back on August 6, 2018. Pfizer has not announced it’s developmental drug at this time but a drug being developed by Zealand's Pharma in which it is developing a rescue pen for hypoglycemia and is currently in Phase 3 trials would qualify as a candidate. Zealand’s drug is “Dasiglucagon” and is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.
All type 1 diabetes patients and the most severely affected type 2 patients depend on insulin injections to maintain blood glucose. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.
Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy and is one of the most feared complications of diabetes treatment. The condition of severe hypoglycemia is most frequently seen in people who inject insulin multiple times per day.
Insulin-dependent diabetics, both type 1 and type 2, can have episodes of severe hypoglycemia, resulting in confusion, loss of consciousness and even death.
With six (6) million or more people across the U.S. using insulin, there's a major need for a treatment for hypoglycemia.
While mild hypoglycemia can be treated by eating or drinking something high in carbohydrates, severe acute episodes require intravenous glucose or an injection of glucagon. Glucagon powder, such as in the GlucaGen HypoKit, requires reconstitution and injection with a syringe. Zealand's approach is a ready-to-use "rescue pen" known as HypoPal.
How common is Diabetes?:
Type 2 diabetes is much more common that type 1. According to the 2017 National Diabetes Statistics Report, there are 30.3 million people in the United States with diabetes. That’s close to 1 in 10 people. Among all these people living with diabetes, 90 to 95 percent have type 2 diabetes.. The percentage of people with diabetes increases with age. Less than 10 percent
of the general population has diabetes, but among those 65 and older, the incidence rate reaches a high of 25.2 percent. Only about 0.18 percent of children under the age of 18 had diabetes in 2015. Men and women get diabetes at roughly the same rate, but incidence rates are higher among certain races and ethnicities. American Indians and Alaskan Natives have the highest prevalence of diabetes among both men and women. The black and Hispanic populations have higher rates of diabetes than non-Hispanic whites.
Less
ReplyReplies (2)10
I wasn't expecting a sharp selloff on the first trading day of the year. Not sure what that was all about. Like you said, not the first time we've seen the stock have a sharp decline on no news. Que sera sera. I added a few shares at 4.24.
Déjà vu. We saw this same game a year ago.
There were 10 new highs in 2019 and I’d be willing to bet there will be many more than that in 2020!
11/12 $4
11/13 $4.20
11/15 $4.22
11/18 $4.33
11/19 $4.535
11/20 $4.735
11/21 $4.80
11/22 $4.99
11/25 $5.06
12/03 $5.13
Wow, like you said, going back to $3.50 to fill the gap. It could even go lower, who knows.
We couldn't hold 5.00 per share but I am optimistic for 2020.
Little to no chance, but if it does will be buying BIGLY
Re: Is ATRS going down to $3.50? IMO and experience YES.
That's for letting us know about the gap at $3.50 and based on that, could you let me know what that means? What should I except with the gap at $3.50? Is ATRS going down to $3.50 or down some, because there is a gap at $3.50. Thank you.
2020 is an election year. When both republican and democrat candidates target big pharma drug prices as the evil enemy (even though drug development costs are high) how will that screw over our profitability, in terms of causing the stock price going down and not up.
Remember, in 2015 Hillary tweeted that drug prices need to come down and that she was going to take on big pharma and that very same day, big pharma stocks tanked down at least 6% and I suspect much more.
Isn't it a dangerous as hell risk to be invested in big pharma in 2020?
If Trump runs and wins, wouldn't that bode well for being invested in fossil fuel stocks instead?
SOS continues to be Bullish on ATRS
A new article with Larry's projections is out today:
https://smithonstocks.com/antares-detailed-sales-and-earnings-projections-for-2020-2021-and-2022-atrs-buy-4-86/
He gives his assumptions on the revenue and P/E as his best estimates.
* * $ATRS Video Chart 12-04-2019 * *
Link to Video - click here to watch the technical chart video
Agreed and hopefully $5 is the new floor and then $6, then $7 and then $222.
5 has been breached! This stock struggled to get past 3 and hold it for so long that 4 seemed impossible. It appears we're finally getting some recognition. Hopefully 5 will hold and become the new floor.
It wants to break $5, but resistance is stopping it.
Isaac Newton - "What goes up must come down."
Yes we took profits
Is it time to bale out and get back in lower then? Or are you a long? With a name like TrendTrade, I'm assuming you are taking a profit now?
called the top here for now....needs to correct
Whats the stock market schedule for this week? Is it only closed on Thanksgiving day?
ATRS GETTING READY TO TEST 10 YEAR HIGH...BOOM!!
Followers
|
125
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4817
|
Created
|
12/31/05
|
Type
|
Free
|
Moderators |
Xyosted & Epi Numbers, as provided by Yahoo Msg Board https://docs.google.com/spreadsheets/d/1UDt42d2XX_h-UrO8wTu7kHkuYyhmKhonTz_OyNrlWWg/edit
Company web site: http://www.antarespharma.com/
Latest Presentation: http://www.antarespharma.com/corporate/
SEC Filling(s): http://www.nasdaq.com/symbol/atrs/sec-filings
Patents: http://tiny.cc/k6d1sw
Clinical Trials http://clinicaltrials.gov/ct2/results?term=antares+pharma
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |